Complement 3 glomerulopathy (C3G)

Clinical trials for Complement 3 glomerulopathy (C3G) explained in plain language.

Never miss a new study

Get alerted when new Complement 3 glomerulopathy (C3G) trials appear

Sign up with your email to follow new studies for Complement 3 glomerulopathy (C3G), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet finished but already full! 2 Completed 2

New drug combo aims to tame rare kidney diseases

Disease control Recruiting now

This Phase 2 study tests a new drug called ADX-038, alone or with another drug (telitacicept), in 30 Chinese adults with kidney diseases caused by an overactive complement system (IgA nephropathy, C3G, or IC-MPGN). The goal is to see if the treatment is safe and can help control …

Matched conditions: COMPLEMENT 3 GLOMERULOPATHY (C3G)

Phase 2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control

Last updated Sep 05, 2026 00:00 UTC

Complement 3 glomerulopathy (C3G)

Get alerted when new Complement 3 glomerulopathy (C3G) trials appear

New drug combo aims to tame rare kidney diseases